Category: Markets
Published: 2026-06-22T17:15:41.000Z
Merck & Co. announced positive results from its Phase 3 ATLAS-UC induction study for tulisokibart, a novel anti-TL1A therapy for ulcerative colitis. The drug met its primary endpoint of clinical remission at week 12 and key secondary endpoints, with a safety profile consistent with previous findings. This milestone reinforces the potential of targeting TL1A for immune dysregulation in ulcerative colitis, and tulisokibart has the broadest development program among investigational anti-TL1A therapies, spanning seven disease indications.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.